GM-CSF is responsible for the cytokine storm. The cytokine storm is responsible for severe Covid and death. Administering lenzilumab after a patient is already hypoxic isn't ideal. The cytokine storm is already on full blast. Once the cytokine storm is on full blast, there are already many other cytokines triggered. The LIVE-AIR trial had 720% efficacy on the primary endpoint for the patients with a CRP<41mg/L. That represented 25% of the patients in the trial. The ACTIV-5 trial might still have great data with those patients. It will be nice when Humanigen has that data to analyze. It will also be nice if they can do a trial for moderate patients. GM-CSF is upstream. Treating it early is obviously ideal.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.